Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 18/20 | 0.79 |
| ▸ | PGR | P06401 | 18/20 | 0.79 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13013754 | 0.88 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL13013621 | 0.88 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL13013837 | 0.88 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL13013595 | 0.88 | AR (0.60) | ARPGRNR3C2 | |
| SCHEMBL16715968 | 0.88 | AR (0.82) | ARPGRNR3C2 | |
| SCHEMBL16404186 | 0.84 | PGR (0.81) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL13013658 | 0.84 | AR (0.57) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL12904852 | 0.83 | PGR (0.55) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL13013637 | 0.83 | PGR (0.75) | ARPGRNR3C2NR1I2NR3C1 | |
| SCHEMBL13013654 | 0.80 | AR (0.58) | ARPGRNR3C2NR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034856-B2 | 17-(1′propenyl)-17-3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317632-A1 | 17-(1'PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | NR5A1, CYP19A1, CYP17A1 | AR 44/4885PGR 8/4885NR3C2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.